Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 

7 Binary Options

US-friendly broker Finpari

 

Enter Stock Symbol:  

Jounce Therapeutics Inc (JNCE)

16.57 -0.40 (-2.36%)

6/23/2017  1:06pm

Open:

17.14

Pre. Close:

16.97

High:

17.68

Low:

16.57

Volume:

57,289

Market Cap:

532.46M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

-

-

Low:

-

-

Close:

-

-

Technical analysis  (as of: 2017-06-23 12:46:06 PM)

Overall:

      

Stoxline posted a BUY today, same as yesterday. This stock seems to continue bullish move. If you bought, continue to hold stock until SELL signal. You are relatively safe to buy now, upward move is expected.

Target:

Six months: 24.93     One year: 29.41

Support:

Support1: 15.13    Support2: 12.59

Resistance:

Resistance1: 21.34    Resistance2: 25.18

Pivot:

17.29

Moving Averages:

MA(5): 16.57     MA(20): 18.39

MA(100): 21.75 -10000000000    MA(250):

MACD:

MACD(12,26): -1.76     Signal(12,26,9): -1.81

%K %D:

%K(14,3): 23.22     %D(3): 18.56

RSI:

RSI(14): 37.93

52-Week:

High: 29.29  Low: 15.13  Change(%): -1.5

Average Vol(K):

3-Month: 152  10-Days 115

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
JNCE has closed above bottom band by 44.5%. Bollinger Bands are 0% narrower than normal.

Headline News

Mon, 12 Jun 2017 09:56:15 GMT
OncoSec Announces Technology Access Program Agreement with Jounce Therapeutics ...

Wed, 25 Jan 2017 07:51:53 GMT
15.74

Fri, 27 Jan 2017 11:13:14 GMT
​Cambridge's Jounce raises hopes as first Mass. biotech of 2017 to go public

Tue, 19 Jul 2016 11:04:43 GMT
Jounce Therapeutics Announces Major Strategic Collaboration with Celgene ...

Wed, 25 May 2016 12:37:25 GMT
Jounce Therapeutics Appoints Barbara G. Duncan to its Board of Directors

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Bio Therapeutic Drugs

Shares Out. (M)

32.17

Shares Float (M)

15.28

% Held by Insiders

% Held by Institutions

Shares Short (K)

358

Shares Short Prior Month (K)

436

Stock Financials

EPS

-1.410

EPS Est. Current Year

-0.650

EPS Est. Next Year

-0.160

EPS Est. Next Quarter

-0.210

Forward EPS

-0.160

Book Value (p.s.)

5.540

PEG Ratio

Profit Margin

-4.22

Operating Margin

-6.63

Return on Assets (ttm)

Return on Equity (ttm)

-2.2

Qtrly Rev. Growth

Gross Profit (p.s.)

1.156

Sales Per Share

EBITDA (p.s.)

-0.042

Qtrly Earnings Growth

Operating Cash Flow (M)

173.71

Levered Free Cash Flow (M)

FoxReading.com

Valuation

P/E

-12.05

P/E Growth Ratio

P/BV

3.07

P/S

71446840.00

P/CF

3.15

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.